secwatch.observer — SEC 8-K summary
======================================

Issuer:     Crinetics Pharmaceuticals, Inc. (CRNX)
CIK:        0001658247
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001658247-25-000018
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Crinetics Q3 net loss $130.1M; PALSONIFY launched for acromegaly after FDA approval
--------------------------------------------------------------------------------

- PALSONIFY (paltusotine) approved by FDA Sept 25 for first-line acromegaly; ~95% of top-priority HCP targets called, ~50% of filled prescriptions reimbursed.
- Q3 2025 net loss $130.1M vs $76.8M YoY; R&D $90.5M (+46%), SG&A $52.3M (+102%) driven by launch and pipeline.
- Cash, equivalents and investments $1.1B; cash burn guidance $340-370M for 2025; runway into 2029.
- Phase 3 CAREFNDR (carcinoid syndrome) and Phase 3 CALM-CAH (CAH) expected to start Q4 2025; Phase 1/2 CRN09682 also Q4.
- TSHR antagonist program shifted to alternative candidate; SST3 IND postponed after preclinical data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/0001658247-25-000018-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658247/000165824725000018/crnx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001658247-25-000018

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer